NF2 mutation contributes to drug resistance in multiple cancer types [89,90], while molecular alterations of NF2 is found in 5% of lung adenocarcinoma patients and 15% of lung squamous cell carcinoma patients [91]. This evidence concerns the gene NF2 and squamous cell lung carcinoma.